© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
None of the people who experienced virologic failure on regimens containing the experimental drug had a viral load of 200 or higher.
More studies link dolutegravir and other drugs to weight gain among people with HIV.
Merck’s experimental HIV drug proves effective and well tolerated
Updating previous, similar findings, researchers have now reported on 96-week data from a pair of ongoing trials.
This finding did not vary based on the dose of the nucleoside reverse transcriptase translocation inhibitor, formerly called MK-8591.
The Food and Drug Administration has approved a new treatment for people living with HIV.
Research in human cells and mice found the antiretroviral suppressed harmful chronic inflammation linked to age-related disorders.
In clinical trials, the single-tablet regimen of Tivicay (dolutegravir) and Epivir (lamivudine) was as effective as a three-drug treatment.
Full 48-week results comparing dolutegravir plus lamivudine with a three-drug combo were presented at the International AIDS Conference.
The FDA approves three new, cheaper combination ARV tablets.
The combo of dolutegravir and lamivudine controlled HIV as well as a triple-drug combo of dolutegravir plus Truvada.
Symfi Lo contains efavirenz, lamivudine and tenofovir disoproxil fumarate (TDF); Cimduo contains TDF and lamivudine.
The trial will test a regimen of Tivicay (dolutegravir) plus Epivir (lamivudine) against Tivicay and Truvada (tenofovir/emtricitabine).
The regimen of Tivicay (dolutegravir) and Epivir (lamivudine) would be a highly cost-effective first-line option and save a great deal.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
